Skip to main content
Premium Trial:

Request an Annual Quote

International VC Firm Still Has Half of $300M Fund Available

NEW YORK, Aug. 27 - German life-science VC firm Techno Venture Management has spent about half of the $296 million fund raised last November, a company official told GenomeWeb.

 

The cash was spent among 13 startup biotechs, said TVM spokeswoman Theresia Wermelskirchen. She added that the company, a specialist in early-stage companies, "still has room for more investments."

 

Munich-based TVM had said last November it planned to focus its investments in early-stage companies developing platform technologies to improve the drug-discovery process, as well as in companies developing therapeutics. Later-stage deals will be considered.

The company said it would be primarily interested in companies based in Germany, Switzerland, Austria, the UK, and the US. It has previously invested in companies such as GPC Biotech, MediGene, DeveloGen, and Evotec BioSystems.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.